Novartis and Samsung ink five-year, $309M expansion to biologics manufacturing partnership

Sam­sung Bi­o­log­ics dis­closed Mon­day that it’s sig­nif­i­cant­ly ex­pand­ing a 2022 pact with No­var­tis to help with the Swiss com­pa­ny’s bi­o­log­ics man­u­fac­tur­ing.

The orig­i­nal $81 mil­lion part­ner­ship from June 2022 will now be a five-year deal worth al­most $391 mil­lion — a $309 mil­lion ex­pan­sion.

A No­var­tis spokesper­son said via email that the com­pa­ny signed a let­ter of in­tent with Sam­sung Bi­o­log­ics “to re­serve the need­ed ca­pac­i­ty for the man­u­fac­tur­ing of bi­o­log­ics drug sub­stances. With the agree­ment in place, Sam­sung Bi­o­log­ics fa­cil­i­ty in Ko­rea would serve as an ad­di­tion­al sup­ply point for Eu­rope and oth­er mar­kets with grow­ing de­mand for No­var­tis bi­o­log­ics.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN